Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

被引：1
|
作者：
Srinivas, Sandy
Narayanan, Sujata
Harshman, Lauren Christine
Pachynski, Russell Kent
Lam, Anthony P.
Fan, Alice C.
Poushnejad, Shermeen
Haas, Denise
Vaishampayan, Ulka N.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
294
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.
    Edenfield, William Jeffery
    Becerra, Carlos
    Langleben, Adrian
    Spira, Alexander I.
    Braiteh, Fadi S.
    Kossler, Kimiko
    Gao, Yuan
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
    Kaern, J
    Baekelandt, M
    Tropé, CH
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (05) : 383 - 389
  • [33] Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer.: A phase II study
    Frasci, G
    Comella, P
    D'Aiuto, G
    Budillon, A
    Barbarulo, D
    Thomas, R
    Capasso, I
    Casaretti, R
    Daponte, A
    Caponigro, F
    Gravina, A
    Maiorino, L
    Caratení, G
    Gentile, A
    Comella, G
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (01) : 13 - 26
  • [34] A phase II study of weekly paclitaxel and doxifluridine (an intermediate metabolite of capecitabine) combination chemotherapy for advanced/recurrent gastric cancer.
    Takeyoshi, I
    Makita, F
    Tanahashi, Y
    Iwazaki, S
    Nakamura, S
    Ogawa, T
    Ishikawa, H
    Ohya, T
    Kawate, S
    Morishita, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 328S - 328S
  • [35] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Mori, K
    Kamiyama, Y
    Kondo, T
    Kano, Y
    Kodama, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (01) : 86 - 90
  • [36] Phase II study of weekly paclitaxel plus 5-fluorouracil in patients with unresectable advanced or recurrent gastric cancer.
    Ninomiya, M
    Kondo, K
    Kojima, H
    Matsuo, K
    Hirabayashi, N
    Nakamura, S
    Kawamura, S
    Kobayashi, M
    Konno, H
    Sakamoto, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 326S - 326S
  • [37] Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study
    Giuseppe Frasci
    Pasquale Comella
    Giuseppe D'Aiuto
    Alfredo Budillon
    Deborah Barbarulo
    Renato Thomas
    Immacolata Capasso
    Rossana Casaretti
    Antonio Daponte
    Francesco Caponigro
    Adriano Gravina
    Luigi Maiorino
    Giacomo Caratení
    Alfonso Gentile
    Giuseppe Comella
    Breast Cancer Research and Treatment, 1998, 49 : 13 - 26
  • [38] Weekly cisplatin plus paclitaxel and concurrent radiotherapy as preoperative treatment of esophageal cancer. A single center phase II study
    Ciardiello, F.
    Orditura, M.
    Diadema, M. R.
    Belli, C.
    Piccirillo, M.
    del Genio, A.
    Di Martino, N.
    Napolitano, V
    Galizia, G.
    Catalano, G.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI49 - XI49
  • [39] Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer
    Kiyoshi Mori
    Yukari Kamiyama
    Tetsuro Kondo
    Yasuhiko Kano
    Tetsuro Kodama
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 86 - 90
  • [40] Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC)
    Hudes, GR
    Celano, P
    Torti, F
    Tabatabai, A
    Murgo, A
    Hussain, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 431S - 431S
12345